<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-119132</identifier>
<setSpec>1695-4033</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Increase in the incidence of invasive pneumococcal disease caused by serotype 19A prior to the implementation of the expanded pneumococcal vaccines</dc:title>
<dc:description xml:lang="en">Objective: To describe the epidemiology, clinical syndromes and microbiological characteristics of serotype 19A as the main cause of invasive pneumococcal disease (IPD) in children admitted to a tertiary hospital in Spain. Methods: A retrospective (1998-2004) and prospective (2005-2009) study was conducted on children with IPD produced by serotype 19A. The study was divided into three periods (P):P1 (1998-2001) when PCV7 had not been commercialized; P2 (2002-2005) with 40% vaccine coverage among children; and P3 (2006-2009) when the vaccine was added to the Childhood Immunization Schedule in Madrid. Results: A total of 155 isolates of Streptococcus pneumoniae (SP) producing IPD were analysed ,with 21 of them being serotype 19A (14%). An increased prevalence of serotype 19A was found:2/45 cases (4.4%) in P1, 3/41 cases (7.3%) in P2 and 16/69 cases (23.2%) in P3. It occurred mostly in children younger than 2 years (16/21; 76%). This serotype was the main cause of meningitis (5/20; 25%), pleural empyema (3/22; 14%) and bacteraemic mastoiditis (2/4; 50%). Thirteen isolates (61.5%) had an MIC &amp;#8805;0.12 &amp;#956;/ml for penicillin in extra-meningeal infections, and 3 of the 5 isolates causing meningitis (60%) had an MIC &amp;#8805;1 &amp;#956;/ml for cefotaxime. Conclusions: Serotype 19A was the main causal agent of IPD in the PCV7 era (P3), with high antibiotic resistance rates. This serotype was responsible for all types of IPD, being the main cause of meningitis (AU)</dc:description>
<dc:creator>Santos Sebastián, M. M</dc:creator>
<dc:creator>González Sánchez, M</dc:creator>
<dc:creator>Rodríguez Fernández, R</dc:creator>
<dc:creator>Saavedra Lozano, J</dc:creator>
<dc:creator>Navarro Gómez, M. L</dc:creator>
<dc:creator>González Martínez, F</dc:creator>
<dc:creator>Hernández-Sampelayo Matos, T</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Describir los aspectos epidemiológicos, clínicos y microbiológicos del serotipo 19A como principal productor de enfermedad neumocócica invasiva (ENI) en un hospital terciario de la Comunidad de Madrid (CAM). Métodos: Estudio retrospectivo (1998-2004) y prospectivo (2005-2009) del serotipo 19A como agente productor de ENI en pediatría entre 1998-2009. Se analizaron 3 periodos de estudio: P1 (1998-2001), previo a la comercialización de la VNC7; P2 (2002-2005), con una cobertura vacunal de 40%, y P3 (2006-2009), cuando la vacuna fue incorporada al calendario vacunal de la CAM. Resultados: Se analizaron un total de 155 muestras de Streptococcus pneumoniae (S. pneumoniae) productoras de ENI; 21 casos producidos por el serotipo 19A (14%). Se detectó un aumento de la prevalencia del serotipo 19A: 2 casos de un total de 45 en P1 (4,4%), 3 de 41 casos en P2 (7,3%) y 16 de 69 casos en P3 (23,2%). Afectó, principalmente, a niños menores de 2 años (16/21; 76%), siendo, globalmente, el principal productor de meningitis (5/20; 25%), así como de empiema pleural (3/22; 14%) y mastoiditis bacteriémica (2/4; 50%). Trece aislamientos (61,5%) presentaron una CMI &amp;#8805; 0,12 &amp;#956;/ml para penicilina en infecciones extrameníngeas y 3 de los 5 casos de meningitis (60%) presentaron una CMI &amp;#8805; 1 &amp;#956;/ml para cefotaxima. Conclusiones: El serotipo 19A se convirtió en el principal agente etiológico productor de ENI en la era de la VNC7 (P3), asociando altas tasas de resistencia antibiótica. Este serotipo produjo todas las formas clínicas de ENI, siendo el principal causante de meningitis (AU)</dc:description>
<dc:source>An Pediatr (Barc);79(5): 288-294, nov. 2013. graf, tab</dc:source>
<dc:identifier>ibc-119132</dc:identifier>
<dc:title xml:lang="es">Aumento de la incidencia de enfermedad neumocócica invasora producida por el serotipo 19A previo a la introducción de las vacunas neumocócicas ampliadas</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d11437^s22080</dc:subject>
<dc:subject>^d35368^s22000</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d8755^s22080</dc:subject>
<dc:subject>^d30241^s22080</dc:subject>
<dc:subject>^d22165</dc:subject>
<dc:subject>^d13683^s22052</dc:subject>
<dc:type>article</dc:type>
<dc:date>201311</dc:date>
</metadata>
</record>
</ibecs-document>
